drugset / Trial / NCT06029673

Cabergoline for Lactation Inhibition After Early Second-Trimester Abortion or Pregnancy Loss

NCT06029673

RandomizedParallel-groupQuadruple-blindPrevention

Summary

Breast pain following second-trimester abortion is common. Breast engorgement and milk leakage following second-trimester perinatal loss and abortion can cause both physical pain and emotional distress. Dopamine agonists have previously been shown to be effective in lactation inhibition for third-trimester fetal/neonatal loss or contraindications to breastfeeding. The investigator's prior work demonstrated that compared to placebo, a single dose of cabergoline was effective in preventing breast symptoms after abortion or loss 18-28 weeks. As lactogenesis starts as early as 16 weeks gestation, the investigators hope to determine the efficacy of cabergoline earlier in the second trimester,16-20 weeks.

Timeline

Start
2024-02-07
Primary completion
2025-06-15
Completion
2025-07-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Cabergoline Small molecule 1 mg Oral

Indications